CAS: 1648843-04-2

SX-682

SX-682 is an orally bioavailable antagonist of the chemokine receptor CCR1, which is derived from advanced medicinal chemistry efforts targeting inflammatory pathways. Its mode of action involves selectively blocking the interaction between CCR1 and its ligands, thereby inhibiting the recruitment and activation of immune cells such as monocytes and macrophages. This action modulates inflammatory responses and has shown promise in dampening pathological inflammation. The compound is being explored for its therapeutic potential in conditions characterized by chronic inflammation, autoimmune disorders, and certain cancer types, where the immune microenvironment plays a critical role in disease progression. By intervening in these chemokine-mediated pathways, SX-682 represents a targeted approach to modulating immune cell behavior, offering insights into novel intervention strategies for controlling inflammatory diseases and potentially augmenting cancer therapy.

SX-682 is an orally available allosteric inhibitor of CXCR1 and CXCR2.Cost-effective and quality-assured.

(2-(((5-((4-Fluorophenyl)Carbamoyl)Pyrimidin-2-Yl)Thio)Methyl)-4-(Trifluoromethoxy)Phenyl)Boronic Acid